Literature DB >> 11819026

Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy.

P De La Cruz1, A Guerrero, J Paniego, I Arranz, A Moreno, F Sánchez De La Cuesta.   

Abstract

The importance in experimental diabetic retinopathy of prostacyclin and nitric oxide (NO), as well as the possible effect of acetylsalicylic acid (ASA), are well known. To investigate the effect of two doses of aspirin in the prevention of retinal ischemia in streptozotocin-diabetic rats, we compared nondiabetic rats and diabetic rats after 1, 2 and 3 months of diabetes, and diabetic rats treated with 2 mg or 10 mg ASA/kg per day p.o. from the first day of diabetes. The parameters determined after 1, 2 and 3 months of development were platelet aggregation, thromboxane B(2) (TxB(2)) production, 6-keto-prostaglandin F(1)(alpha) (stable metabolite of prostacyclin), NO, plasma nitrites/nitrates, and percentage retinal surface occupied by horseradish peroxidase (HRP)-permeable vessels. In diabetic rats platelet aggregation and thromboxane concentration were increased, and prostacyclin, NO and area occupied by HRP-permeable vessels were decreased. Acetylsalicylic acid reduced platelet aggregation, and lowered thromboxane production by 82%-99%. Prostacyclin production was inhibited by 92%-95% with 10 mg ASA/kg per day, and by 8%-20% with 2 mg ASA/kg per day. In diabetic rats NO production increased after 2 and 3 months of treatment to levels seen in nondiabetic rats. The reduction in HRP-permeable retinal surface decreased from a maximum of 87% in DR to 51% after treatment with 2 mg ASA/kg per day, and to 62% after 10 mg ASA/kg per day. We conclude that ASA (2 mg/kg per day and 10 mg/kg per day) increased NO production in streptozotocin-diabetic rats and reduced the degree of retinal ischemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11819026     DOI: 10.1007/s00210-001-0507-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  4 in total

1.  Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.

Authors:  J P De La Cruz; M A Villalobos; R Escalante; A Guerrero; M M Arrebola; F Sánchez de La Cuesta
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids.

Authors:  J A González-Correa; M M Arrebola; I M Ureña; D Ruiz-Villafranca; J Muñoz-Marín; A Guerrero; F Sánchez de la Cuesta; J P De La Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-12-16       Impact factor: 3.000

3.  Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist.

Authors:  William S Wright; Jodine E Messina; Norman R Harris
Journal:  Exp Eye Res       Date:  2008-11-01       Impact factor: 3.467

4.  Ozagrel attenuates early streptozotocin-induced constriction of arterioles in the mouse retina.

Authors:  William S Wright; Norman R Harris
Journal:  Exp Eye Res       Date:  2008-01-09       Impact factor: 3.467

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.